Tilak Mandadi Sells 69,551 Shares of CVS Health (NYSE:CVS) Stock

CVS Health Corporation (NYSE:CVS) EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

CVS Health Price Performance

CVS stock traded up $1.67 during mid-day trading on Monday, reaching $92.22. 12,023,251 shares of the company’s stock were exchanged, compared to its average volume of 8,588,751. The company has a market cap of $117.67 billion, a price-to-earnings ratio of 40.63, a price-to-earnings-growth ratio of 0.88 and a beta of 0.60. The stock’s 50 day moving average is $76.86 and its 200 day moving average is $78.03. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $92.77.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts expect that CVS Health Corporation will post 7.48 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health’s dividend payout ratio is currently 117.18%.

Hedge Funds Weigh In On CVS Health

Several hedge funds and other institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. increased its holdings in shares of CVS Health by 0.6% in the first quarter. PNC Financial Services Group Inc. now owns 588,829 shares of the pharmacy operator’s stock valued at $42,290,000 after purchasing an additional 3,507 shares during the last quarter. Oslo Pensjonsforsikring AS acquired a new stake in shares of CVS Health in the first quarter valued at approximately $32,137,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of CVS Health in the first quarter valued at approximately $139,000. Commerzbank Aktiengesellschaft FI increased its holdings in shares of CVS Health by 87.5% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 102,099 shares of the pharmacy operator’s stock valued at $7,333,000 after purchasing an additional 47,646 shares during the last quarter. Finally, Beta Wealth Group Inc. increased its holdings in shares of CVS Health by 3.6% in the first quarter. Beta Wealth Group Inc. now owns 5,828 shares of the pharmacy operator’s stock valued at $419,000 after purchasing an additional 203 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: TD Cowen raised its price target on CVS Health to $110 from $105 and reiterated a buy rating, signaling more upside after the earnings beat and guidance increase. TD Cowen adjusts price target on CVS Health to $110 from $105
• Positive Sentiment: Analysts and commentary continue to highlight CVS as a value stock, with articles pointing to attractive valuation, improving fundamentals, and renewed optimism after the latest quarter. Zacks: Here’s Why CVS Health (CVS) is a Strong Value Stock
• Positive Sentiment: Recent coverage from investors and media has emphasized broad-based strength in Aetna, Health Services, and Pharmacy & Consumer Wellness, reinforcing the view that CVS’s turnaround is gaining traction. A Look At CVS Health (CVS) Valuation After Earnings Beat And Raised 2026 Guidance
• Neutral Sentiment: CVS has also been mentioned in broader market and healthcare roundups, including CNBC’s “Final Trades” and weekly healthcare headline coverage, which may support attention but do not materially change the operating story. Nvidia, CVS Health, Vertiv and an energy stock on CNBC’s ‘Final Trades’
• Neutral Sentiment: Some coverage focuses on CVS pharmacists’ community role and sector trends, which is supportive of the brand but unlikely to move the stock by itself. How CVS Health pharmacists support Florida communities

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of recent analyst reports. Wolfe Research decreased their target price on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. HSBC raised their target price on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft raised their target price on CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday. Sanford C. Bernstein upgraded CVS Health from a “market perform” rating to an “outperform” rating and raised their target price for the company from $91.00 to $94.00 in a research report on Thursday, March 12th. Finally, UBS Group raised their target price on CVS Health from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $96.12.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.